MedPharm's 'Patch-in-a-Can' Drug Delivery Tech Granted New Patents

Related tags Drug delivery Pharmacology

MedPharm's 'Patch-in-a-Can' Drug Delivery Tech Granted New Patents
Having been granted a series of patents, MedSpray’s ‘patch-in-a-can’ spray-on-film technology can offer dermatological, topical and transdermal drug delivery, says MedPharm.

The MedSpray technology - which uses spray-on-films directly on the skin in order to offer drug delivery in an extended release form – has received patent approval in a number of countries throughout Europe, North America, and the rest of the world.

Andrew Muddle, MedPharm’s CEO, told in-Pharmatechnologist.com that while there are other technologies that use a similar drug delivery mechanism, “MedSpray is unique in its performance and its pressurised metered dose aerosol including propellant.”

The patch is manufactured as a solution but manifests itself into a microfine occlusive film when administered in order to deliver a number of drugs – including anesthetics, antibacterials, antifungals and anti-inflammatory drugs - both directly on the skin and transdermally.

According to the company, the technology has been coined a ‘patch-in-a-can’ as it blends a transdermal patch with an aerosol dosage form. Furthermore it can be manipulated to suit specific drugs and diseases, with delivery for both extended or modified release.

The technology has been trialled with over 20 drugs and “will be relatively quick to get to the market,” ​said Muddle, though with clinical trials this may take between two and four years.

He also confirmed MedPharm did not have its own pipeline but rather “licenses early and expects [the] licensee to advance the projects.”

“Our licensees are pharm and biotech companies,”​ he continued, adding “one example is Sinclair Pharma who has licensed [the technology] for an antifungal project,” ​in 2010.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Product Brochure

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Related suppliers

Follow us

Products

View more

Webinars